Child and Adolescent Immunization Schedule by Age 소아및 청소년 연령별 예방접종 일정
Recommendations for Ages 18 Years or Younger, United States, 2024
Sources: Red Book 2024
Note: No Korean version
For further information, please visit “drleepediatrics.com” and then Search.
더 많은 정보를 얻으시려면 drleepediatrics.com에서 Search에서 찾으세요
To make vaccination recommendations, healthcare providers should:
- Determine recommended vaccine by age (Table 1 – By Age)
- Determine recommended interval for catch-up vaccination (Table 2 – Catch-up)
- Assess need for additional recommended vaccines by medical condition or other indication (Table 3 – By Medical Indication)
- Review vaccine types, frequencies, intervals, and considerations for special situations (Notes)
- Review contraindications and precautions for vaccine types (Appendix)
- Review new or updated ACIP guidance (Addendum)
Legend
| Range of recommended ages for all children | Range of recommended ages for catch-up vaccination |
Range of recommended ages for certain high-risk groups | Recommended vaccination can begin in this age group | Recommended vaccination based on shared clinical decision-making | No recommendation/ not applicable |
Birth to 15 Months
These recommendations must be read with the notes that follow. For those who fall behind or start late, provide catch-up vaccination at the earliest opportunity as indicated by the green bars. To determine minimum intervals between doses, see the catch-up schedule (Table 2).
| Vaccine and other immunizing agents | Birth | 1 mo | 2 mos | 4 mos | 6 mos | 9 mos | 12 mos | 15 mos | |||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Respiratory syncytial virus (RSV-mAb [Nirsevimab]) |
1 dose depending on maternal RSV vaccination status, See notes | 1 dose (8 through 19 months), See notes | |||||||||
| Hepatitis B (HepB) |
1st dose | ←2nd dose→ | ←3rd dose→ | ||||||||
| Rotavirus (RV) RV1 (2-dose series); RV5 (3-dose series) |
1st dose | 2nd dose | See notes | ||||||||
| Diphtheria, tetanus, & acellular pertussis (DTaP: <7 yrs) |
1st dose | 2nd dose | 3rd dose | ←4th dose→ | |||||||
| Haemophilus influenzae type b (Hib) |
1st dose | 2nd dose | See notes | ←3rd or 4th dose, See notes→ |
|||||||
| Pneumococcal conjugate (PCV15, PCV20) |
1st dose | 2nd dose | 3rd dose | ←4th dose→ | |||||||
| Inactivated poliovirus (IPV: <18 yrs) |
1st dose | 2nd dose | ←3rd dose→ | ||||||||
| COVID-19 (1vCOV-mRNA, 1vCOV-aPS) |
1 or more doses of updated (2023–2024 Formula) vaccine (See notes) |
||||||||||
| Influenza (IIV4) | Annual vaccination 1 or 2 doses | ||||||||||
 Influenza (LAIV4) |
|||||||||||
| Measles, mumps, rubella (MMR) |
See notes | ←1st dose→ | |||||||||
| Varicella (VAR) |
←1st dose→ | ||||||||||
| Hepatitis A (HepA) |
(See notes) | ←2-dose series, See notes→ | |||||||||
| Tetanus, diphtheria, & acellular pertussis (Tdap: ≥7 yrs) |
|||||||||||
| Human papillomavirus (HPV) |
|||||||||||
| Meningococcal (MenACWY-CRM ≥2 mos, MenACWY-TT ≥2years) |
See notes | ||||||||||
| Meningococcal B (MenB-4C, MenB-FHbp) |
|||||||||||
| Respiratory syncytial virus vaccine (RSV [Abrysvo]) |
|||||||||||
| Dengue (DEN4CYD: 9-16 yrs) |
|||||||||||
| Mpox | |||||||||||
18 Months to 18 Years
| Vaccine and other immunizing agents | 18 mos |
19-23 mos |
2-3 yrs |
4-6 yrs |
7-10 yrs |
11-12 yrs |
13-15 yrs |
16 yrs |
17-18 yrs |
||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Respiratory syncytial virus (RSV-mAb [Nirsevimab]) |
1 dose (8 through 19 months), See notes | ||||||||||||||||||||||
| Hepatitis B (HepB) |
←3rd dose→ | ||||||||||||||||||||||
| Rotavirus (RV) RV1 (2-dose series); RV5 (3-dose series) |
|||||||||||||||||||||||
| Diphtheria, tetanus, & acellular pertussis (DTaP: <7 yrs) |
←4th dose→ | 5th dose | |||||||||||||||||||||
| Haemophilus influenzae type b (Hib) |
|||||||||||||||||||||||
| Pneumococcal conjugate (PCV15, PCV20) |
|||||||||||||||||||||||
| Inactivated poliovirus (IPV: <18 yrs) |
←3rd dose→ | 4th dose | See notes |
||||||||||||||||||||
| COVID-19 (1vCOV-mRNA, 1vCOV-aPS) |
1 or more doses of updated (2023–2024 Formula) vaccine (See notes) |
||||||||||||||||||||||
| Influenza (IIV4) | Annual vaccination 1 or 2 doses | Annual vaccination 1 dose only | |||||||||||||||||||||
Influenza (LAIV4) |
Annual vaccination 1 or 2 doses
|
Annual vaccination 1 dose only | |||||||||||||||||||||
| Measles, mumps, rubella (MMR) |
2nd dose | ||||||||||||||||||||||
| Varicella (VAR) |
2nd dose | ||||||||||||||||||||||
| Hepatitis A (HepA) |
← 2-dose series, See notes→ | ||||||||||||||||||||||
| Tetanus, diphtheria, & acellular pertussis (Tdap: ≥7 yrs) |
1 dose | ||||||||||||||||||||||
| Human papillomavirus (HPV) |
See notes | ||||||||||||||||||||||
| Meningococcal (MenACWY-CRM ≥2 mos, MenACWY-TT ≥2years) |
See notes | 1st dose | 2nd dose | ||||||||||||||||||||
| Meningococcal B (MenB-4C, MenB-FHbp) |
See notes | ||||||||||||||||||||||
| Respiratory syncytial virus vaccine (RSV [Abrysvo]) |
Seasonal administration during pregnancy, See notes |
||||||||||||||||||||||
| Dengue (DEN4CYD: 9-16 yrs) |
Seropositive in endemic dengue areas (See notes) |
||||||||||||||||||||||
| Mpox | |||||||||||||||||||||||
To make vaccination recommendations, healthcare providers should:
- Determine recommended vaccine by age (Table 1 – By Age)
- Determine recommended interval for catch-up vaccination (Table 2 – Catch-up)
- Assess need for additional recommended vaccines by medical condition or other indication (Table 3 – By Medical Indication)
- Review vaccine types, frequencies, intervals, and considerations for special situations (Notes)
- Review contraindications and precautions for vaccine types (Appendix)
- Review new or updated ACIP guidance (Addendum)
Recommended by the Advisory Committee on Immunization Practices (ACIP) and approved by the Centers for Disease Control and Prevention (CDC), American Academy of Pediatrics (AAP), American Academy of Family Physicians (AAFP), American College of Obstetricians and Gynecologists (ACOG), American College of Nurse-Midwives (ACNM), American Academy of Physician Associates (AAPA), and National Association of Pediatric Nurse Practitioners (NAPNAP).
The comprehensive summary of the ACIP recommended changes made to the child and adolescent immunization schedule can be found in the January 11, 2024 MMWR.
Report
- Suspected cases of reportable vaccine-preventable diseases or outbreaks to your state or local health department
- Clinically significant adverse events to the Vaccine Adverse Event Reporting System (VAERS) at www.vaers.hhs.gov or (800-822-7967)
Questions or comments
Contact www.cdc.gov/cdc-info or 800-CDC-INFO (800-232-4636), in English or Spanish, 8 a.m.–8 p.m. ET, Monday through Friday, excluding holidays.
Note: No Korean version